[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619409":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":34,"locations":44,"responsibleParty":62,"collaborators":22,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":22,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":22,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":22,"overallStatus":83,"whyStopped":22,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"intramuscular injection group (IM group)","EXPERIMENTAL","patients were allocated to receive the same standard antiviral therapy as the control group. Additionally, after routine physical examinations and vital sign monitor, they received 8 mg dexamethasone palmitate administered via intramuscular injection (IM group)",[13],"Drug: intramuscular injection (IM group) or intravenous infusion (IV group)",{"label":15,"type":10,"description":16,"interventionNames":17},"intravenous infusion group (IV group)","patients were allocated to receive the same standard antiviral therapy as the control group. Additionally, after routine physical examinations and vital sign monitor, they received 8 mg dexamethasone palmitate administered via intravenous infusion",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"control group","NO_INTERVENTION","HZ patients with onset of skin lesions within 72 hours received a standard seven-day course antiviral therapy with famciclovir 500 mg three times daily. Besides, they received daily 300 mg pregabalin in divided doses (150 mg\u002F12 hours). Once the patient report mild pain (VAS ≤ 3), the trial for reducing the pregabalin dose was done. If the VAS value increased to more than 3, the patient was returned to the last controllable pregabalin dose. Furthermore, nonsteroidal anti-inflammatory drug celecoxib (200 mg on request, up to two times daily) and tramadol (100 mg on request, up to 400mg daily) will be available for as-needed analgesia, so that a sufficient pain therapy is guaranteed.",null,[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":22},"DRUG","intramuscular injection (IM group) or intravenous infusion (IV group)","after routine physical examinations and vital sign monitor, they received 8 mg dexamethasone palmitate administered via intramuscular injection (IM group) or intravenous infusion (IV group)",[9,15],[30],{"name":31,"affiliation":32,"role":33},"Fang Luo","Beijing Tiantan Hospital, Capital Medical University,Beijing, China","STUDY_CHAIR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":22,"email":39},"Xiangjun Zhou, Dr.","CONTACT","010-59976664","zhouxiangjun963@163.com",{"name":41,"role":37,"phone":42,"phoneExt":22,"email":43},"Chunmei Zhao, Dr.","13611326978","13611326978@163.com",[45],{"facility":5,"status":22,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Beijing","Beijing Municipality","100071","China","CN",{"type":52,"coordinates":53},"Point",[54,55],116.39723,39.9075,{"lat":55,"lon":54},[58],{"name":59,"role":37,"phone":60,"phoneExt":22,"email":61},"Jing Shang, Dr.","010-59978555","ttyyirb@163.com",{"type":63,"investigatorFullName":31,"investigatorTitle":5,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"PRINCIPAL_INVESTIGATOR","100619409","efficacy-and-safety-of-intravenous-dexamethasone-palmitate-treatments-in-acute-and-subacute-herpes-zoster-pain-100619409",false,"NCT07344246","Efficacy and Safety of Intravenous Dexamethasone Palmitate Treatments in Acute and Subacute Herpes Zoster Pain","Efficacy and Safety of Systemic Dexamethasone Palmitate Treatments in Acute and Subacute Herpes Zoster Pain：a Randomized, Prospective, Multicenter, Blinded Endpoint, Open-label Controlled Trial","Inclusion Criteria:\n\n\\- 1. Patients with onset of HZ rash less than 90 days. 2. HZ affected the trigeminal nerves (ophthalmic\u002F maxillary\u002F mandibular nerve). 3. Aged 18 to 75 years (inclusive). 4. Pain intensity ≥ 7 cm on a visual analogue scale (VAS) with 0= 'no pain' to 10='unbearable pain'.\n\n5\\. Tender point count \\> 4. 6. Agreed to sign the informed consent form.\n\nExclusion Criteria:\n\n1. Infection at the puncture site.\n2. Poor general situation unable to be treated.\n3. A history of abuse of narcotics.\n4. Non-compliance or inability to complete the self-evaluation questionnaires.\n5. Pregnancy or lactation.\n6. Patients using immunosuppressants and those with severe systemic diseases such as hematological malignancies, cancers, or autoimmune disorders.","ALL","18 Years","75 Years",{"count":75,"type":76},954,"ESTIMATED","INTERVENTIONAL",[79],"NA","This is a randomized, prospective, multicenter, open-label, blinded-endpoint study investigating the efficacy and safety of dexamethasone palmitate (DXP) for treating acute and subacute herpes zoster (shingles) pain.\n\nThe study consists of four parallel sub-studies, each designed to answer a specific question:\n\nStudy 1: Compares intramuscular (IM) vs. intravenous (IV) administration of DXP (8mg) against standard therapy alone.\n\nStudy 2: Compares two different IV doses of DXP (4mg vs. 8mg) against standard therapy.\n\nStudy 3: For HZ on the body trunk, compares IM injection vs. tender point infiltration vs. paravertebral nerve block (all containing 8mg DXP).\n\nStudy 4: For HZ on the face (trigeminal nerve), compares IM injection vs. tender point infiltration vs. trigeminal nerve block (all containing 8mg DXP).\n\nApproximately 558 adult patients with HZ rash onset within 90 days and significant pain (VAS ≥7) will be enrolled across the studies. All patients receive standard background therapy, including antiviral medication (famciclovir), pregabalin, and rescue analgesics.\n\nThe primary outcome is the change in pain intensity (Visual Analogue Scale, VAS) over 6 months. Secondary outcomes include the incidence of postherpetic neuralgia (PHN) at 3 and 6 months, consumption of pain medications, patient satisfaction, quality of life, and safety.\n\nThe goal is to determine if DXP, through its targeted anti-inflammatory action, provides superior pain relief and PHN prevention compared to standard care, with a favorable safety profile across different administration routes.",[82],"Herpes Zoster Pain","NOT_YET_RECRUITING","2026-01-07",{"date":86,"type":87},"2026-01-15","ACTUAL",{"date":89,"type":76},"2026-02-01",{"date":91,"type":76},"2028-12-01",{"name":5,"class":6},1]